Sulfadiazine-trimethoprim combination in the treatment of urinary tract infections.
In a clinical double-blind study on 198 patients with a urinary tract infection, no differences were found between comparable groups treated with either sulfadiazine (SD) 1,000 MG/trimethoprim (TM) 320 mg or sulfamethoxazole (SM) 1,600 mg/trimethoprim 320 g daily for 2 weeks. The favorable results were obtained according to the bacteriological control in 85 and 79%, respectively. Also the incidence of side effects was the same (22 and 24%, resp.). The number of cases within which the treatment had to be discontinued did not differ percentually, either (6.6 and 8.4%, resp.). Based on the bacteriological sensitivity tests and the clinical trial, the authors conclude that TM can be combined with SD as well as with SM. Pharmacokinetic advantages, like a lower protein-binding and a lesser metabolism, may even make SD more preferable.
D000208:Acute Disease; D000328:Adult; D000368:Aged; D001424:Bacterial Infections / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004338:Drug Combinations; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011704:Pyelonephritis / Q000188:drug therapy; D013411:Sulfadiazine / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D013420:Sulfamethoxazole / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D014295:Trimethoprim / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D014552:Urinary Tract Infections / Q000188:drug therapy*
D004338:Drug Combinations; D013411:Sulfadiazine; D014295:Trimethoprim; D013420:Sulfamethoxazole